About

My name is Charlie Petty, and I'm a life sciences and technology investor living in New York City with my wife and two young children. I work on Public Goods Stripe and am the co-head of Intercept, a $500m innovation fund focused on respiratory virus elimination.

Before Stripe, I worked at the Global Health Investment Corporation and co-founded Adjuvant Capital, an investment firm focused on global public health. Previously, I worked for the Global Health Investment Fund and had a career in industrial technology private equity at Artemis Capital Partners and Axia Partners. For two years after college, I lived in Haiti and worked as a financial analyst for the country's largest microfinance bank.

I have been involved with investments in Aceris Biosciences, Curevo Vaccine (acquired by Eli Lilly), Vaccine Company (acquired by Eli Lilly), Alydia Health (acquired by Merck), Iantech (acquired by Carl Zeiss), Medicines Development for Global Health (PRV acquired by Novo Nordisk), Eubiologics (KOSDQ listed), Terrestrial Bio, Foundry, Minervax, Vitrivax, Centivax, Excision Biotechnologies, ChromaCode, and Codagenix.

I serve on a number of nonprofit boards, including the Council on Strategic Risks, Blueprint Biosecurity, ProEquip Inc., Bellevue Literary Press, and the Mirror Biology Dialogues Fund.

Writing

• Ending respiratory infections

Podcasts

• I went on Ross Rheingans-Yoo's podcast, Development and Research
• I went on the Foundation for American Innovation's podcast, The Frontier

Public health investing coverage

• Stripe, Anthropic and OpenAI are backing an effort to stop respiratory infections
• Stripe and Anthropic invest in combating respiratory diseases
• Eli Lilly Will Buy Three Vaccine Developers
• Adjuvant Capital Raises $300 Million Global-Health Venture Fund